Polaris AI Pharma Corp
041910
Company Profile
Business description
Polaris AI Pharma Corp is engaged in the production of raw pharmaceutical ingredients. It focuses on generic drugs and produces about 40 types of raw medicines, including asthma treatments, gastric ulcer treatments, and alcohol dependence treatments, and supplies them domestically and internationally.
Contact
25 Balangongdan-ro, Hyangnam-eup
Gyeonggi-do
Hwaseong-si
KORT: +82 318314800
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
164
Stocks News & Analysis
stocks
Strong result for ASX insurer but not the new norm
Stellar first half profits but increasing competition will lower future rate increases.
stocks
Eli Lilly earnings: Weak Orforglipron obesity data weighs down a strong quarter
With today’s share drop, we think Lilly stock looks fairly valued.
stocks
Solid 2025 for A-REIT but development activity will weigh on 2026
Positive news for income investors as yield exceeds 5%.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,108.10 | 31.50 | 0.35% |
| CAC 40 | 7,743.00 | 33.68 | 0.44% |
| DAX 40 | 24,162.86 | 29.64 | -0.12% |
| Dow JONES (US) | 44,175.61 | 206.97 | 0.47% |
| FTSE 100 | 9,095.73 | 5.04 | -0.06% |
| HKSE | 24,869.54 | 10.72 | 0.04% |
| NASDAQ | 21,450.02 | 207.32 | 0.98% |
| Nikkei 225 | 41,820.48 | 761.33 | 1.85% |
| NZX 50 Index | 12,938.70 | 94.07 | 0.73% |
| S&P 500 | 6,389.45 | 49.45 | 0.78% |
| S&P/ASX 200 | 8,837.20 | 30.10 | 0.34% |
| SSE Composite Index | 3,635.78 | 0.65 | 0.02% |